Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 17, 2016 - Issue 8
Submit an article Journal homepage
457
Views
5
CrossRef citations to date
0
Altmetric
Review

Current and emerging treatment options in the management of advanced ovarian cancer

Victor Rodriguez-FreixinosDivision of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
,
Helen J. MackayDivision of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada
,
Katherine KarakasisDivision of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
&
Amit M. OzaDivision of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, CanadaCorrespondence[email protected]
Pages 1063-1076 | Received 03 Nov 2015, Accepted 24 Feb 2016, Published online: 16 Mar 2016

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Domenica Lorusso, Elisa Tripodi, Giuseppa Maltese, Stefano Lepori, Ilaria Sabatucci, Giorgio Bogani & Francesco Raspagliesi. (2018) Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. Drug Design, Development and Therapy 12, pages 1501-1509.
Read now

Articles from other publishers (4)

Alexia T. Kedves, Scott Gleim, Xiaoyou Liang, Dennis M. Bonal, Frederic Sigoillot, Fred Harbinski, Sneha Sanghavi, Christina Benander, Elizabeth George, Prafulla C. Gokhale, Quang-De Nguyen, Paul T. Kirschmeier, Robert J. Distel, Jeremy Jenkins, Michael S. Goldberg & William C. Forrester. (2017) Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C. Journal of Clinical Investigation 127:12, pages 4554-4568.
Crossref
Shuo Chen, Dan-Dan Wu, Xiu-Bo Sang, Li-Li Wang, Zhi-Hong Zong, Kai-Xuan Sun, Bo-Liang Liu & Yang Zhao. (2017) The lncRNA HULC functions as an oncogene by targeting ATG7 and ITGB1 in epithelial ovarian carcinoma. Cell Death & Disease 8:10, pages e3118-e3118.
Crossref
Angiolo Gadducci & Maria Elena Guerrieri. (2017) PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic. Critical Reviews in Oncology/Hematology 114, pages 153-165.
Crossref
Xiaofei Zhu, Mingde Ji, Yue Han, Yuanyuan Guo, Wenqiang Zhu, Feng Gao, Xuewen Yang & Chunbing Zhang. (2017) PGRMC1-dependent autophagy by hyperoside induces apoptosis and sensitizes ovarian cancer cells to cisplatin treatment. International Journal of Oncology 50:3, pages 835-846.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.